8-K: Kyverna Advances Autoimmune Therapies, Reports Q2 Loss

Kyverna Therapeutics provides a business update and second quarter 2025 financial results, highlighting progress in its neuroimmunology CAR T franchise and a strong cash position.

Summary

• Kyverna Therapeutics reported a net loss of $42.1 million for the quarter ended June 30, 2025, compared to a net loss of $28.8 million for the same period in 2024.
• Research and Development (R&D) expenses increased to $35.8 million in Q2 2025 from $27.3 million in Q2 2024.
• General and Administrative (G&A) expenses rose to $8.6 million in Q2 2025 from $6.1 million in Q2 2024.
• The company held $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing a cash runway into 2027.
• Patient enrollment for the registrational Phase 2 trial of KYV-101 in Stiff Person Syndrome (SPS) was completed in Q2 2025, with topline data and BLA submission anticipated in 1H 2026.
• The registrational Phase 3 KYV-101 trial in Myasthenia Gravis (MG) will include approximately 60 patients, with enrollment expected to initiate by year-end 2025; interim Phase 2 data is expected in Q4 2025.
• Enrollment for Phase 1 Lupus Nephritis (LN) trials (KYSA-1 and KYSA-3) has concluded, with full data to be shared in a peer-reviewed publication in 2026.
• Investigational New Drug (IND) application for KYV-102, a next-generation CAR T therapy, is expected to be filed in Q4 2025.
• Phase 1 investigator-initiated trial (IIT) data for KYV-101 in Multiple Sclerosis (MS) will be showcased in Q3 2025, and Phase 1/2 IIT data for KYV-101 in Rheumatoid Arthritis (RA) will be highlighted in Q4 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong clinical execution with key milestones achieved and a robust pipeline progression, supported by a healthy cash runway into 2027. While net losses increased, this is typical for a clinical-stage biotech investing heavily in R&D. The positive clinical and regulatory advancements outweigh the expected financial burn.

Positives

• Completed patient enrollment for the registrational Phase 2 trial of KYV-101 in Stiff Person Syndrome (SPS) in Q2 2025, remaining on track for topline data and BLA submission in 1H 2026.
• Successfully concluded an end-of-Phase 2 meeting with the FDA for Myasthenia Gravis (MG), leading to the expansion of the KYSA-6 trial to include a Phase 3 portion with approximately 60 patients.
• Anticipates initiating enrollment for the registrational Phase 3 MG trial by year-end 2025 and reporting interim Phase 2 MG data in Q4 2025.
• Maintains a strong cash position of $211.7 million as of June 30, 2025, projected to provide a cash runway into 2027, supporting key milestones including the first BLA filing and Phase 3 trial.
• Advancing KYV-102, a next-generation CAR T therapy designed to broaden access by eliminating apheresis, with an IND application expected in Q4 2025.
• Exploring additional indications for KYV-101 in Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA), with Phase 1 IIT data for MS expected in Q3 2025 and Phase 1/2 IIT data for RA in Q4 2025.
• Appointed Marc Grasso, M.D., as Chief Financial Officer, bringing over 25 years of relevant experience to the executive team.

Negatives

• Reported a net loss of $42.1 million for Q2 2025, an increase from $28.8 million in Q2 2024.
• Research and Development (R&D) expenses increased to $35.8 million in Q2 2025 from $27.3 million in Q2 2024, indicating higher operational burn.
• General and Administrative (G&A) expenses increased to $8.6 million in Q2 2025 from $6.1 million in Q2 2024.
• Cash, cash equivalents, and marketable securities decreased to $211.7 million as of June 30, 2025, from $285.979 million as of December 31, 2024.
• Interest income decreased to $2.364 million in Q2 2025 from $4.694 million in Q2 2024.

Risks

• Uncertainties related to market conditions.
• The possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission.
• Intellectual property rights.

Future Outlook

Kyverna Therapeutics anticipates continued momentum in the second half of 2025 with the initiation of its Phase 3 registrational trial in Myasthenia Gravis (MG), which is designed to be efficient and well-powered given observed clinical effect size. The company is well-positioned to deliver on multiple near-term value-creating milestones, including interim Phase 2 MG data readout in Q4 2025, and anticipated topline registrational data for Stiff Person Syndrome (SPS) and Biologics License Application (BLA) filing in 1H 2026. The company also plans to file an Investigational New Drug (IND) application for KYV-102 in Q4 2025, aiming to broaden patient access by eliminating apheresis, and will continue to explore additional indications for KYV-101.

Management Comments

• "The second quarter was marked by continued strong execution of our focused strategy, as we achieved key clinical and regulatory milestones to advance our potential first-in-class neuroimmunology CAR T franchise."
• "We anticipate this momentum will continue in the second half of the year with the initiation of our Phase 3 registrational trial in MG. We believe this is an efficient and well-powered trial given the substantial clinical effect size that has been observed in this patient population treated with KYV-101."
• "More broadly, we are well-positioned to deliver on multiple near-term value-creating milestones with our interim Phase 2 MG data readout expected in the fourth quarter of this year as well as anticipated topline registrational data for SPS and BLA filing in the first half of next year."
• "We look forward to sharing more details on these programs at our upcoming KOL event, where we will highlight KYV-101’s differentiated clinical profile, our Phase 3 trial design for MG and the market opportunity for our neuroimmunology franchise."

Industry Context

This announcement positions Kyverna Therapeutics as a key player in the rapidly evolving field of cell therapies for autoimmune diseases, particularly within neuroimmunology. The advancement of CAR T-cell therapies like KYV-101 for conditions such as Stiff Person Syndrome and Myasthenia Gravis represents a significant area of innovation, aiming to provide durable, drug-free remission. The development of KYV-102, designed to simplify the manufacturing process by eliminating apheresis, addresses a critical barrier to broader adoption of cell therapies, potentially expanding market access and competitive advantage in the autoimmune space.

Comparison to Industry Standards

• The filing states that a 'substantial clinical effect size' has been observed in the Myasthenia Gravis patient population treated with KYV-101, suggesting strong efficacy, but no specific comparable companies, projects, or quantitative results are provided for direct benchmarking against industry standards.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant value creation through successful clinical trial outcomes and regulatory approvals, but also continued financial losses and potential future dilution.
• Patients: Potential for new, transformative cell therapies for severe autoimmune diseases like Stiff Person Syndrome, Myasthenia Gravis, Lupus Nephritis, Multiple Sclerosis, and Rheumatoid Arthritis.
• Employees: Continued employment and growth opportunities as the company advances its clinical programs and expands its pipeline.
• Creditors: Financial stability supported by a strong cash position and projected runway into 2027.

Next Steps

• Host a virtual KOL event on August 28, 2025, to discuss KYV-101's clinical profile, MG Phase 3 trial design, and market opportunity.
• Report Phase 1 IIT data of KYV-101 in Multiple Sclerosis (MS) in Q3 2025.
• Report interim Phase 2 data for Myasthenia Gravis (MG) in Q4 2025.
• Initiate enrollment for the registrational Phase 3 trial in Myasthenia Gravis (MG) by year-end 2025.
• Report Phase 1/2 IIT data of KYV-101 in Rheumatoid Arthritis (RA) in Q4 2025.
• File an Investigational New Drug (IND) application for KYV-102 in Q4 2025.
• Report topline registrational Phase 2 data for Stiff Person Syndrome (SPS) in 1H 2026.
• Submit Biologics License Application (BLA) for Stiff Person Syndrome (SPS) in 1H 2026.
• Report full Phase 1 data from Lupus Nephritis (LN) trials in a peer-reviewed publication in 2026.

Key Dates

Recommendation

Kyverna Therapeutics is making significant clinical progress with its lead CAR T-cell therapy, KYV-101, advancing multiple registrational trials and expanding its pipeline. The strong cash position provides a runway into 2027, mitigating immediate funding concerns. However, as a clinical-stage company, it remains pre-revenue with increasing operational losses, which is typical but carries inherent risks related to trial outcomes and regulatory approvals. The stock's performance will likely be highly sensitive to upcoming data readouts and BLA filings. Given the balance of promising pipeline developments and the inherent risks and financial burn of a clinical-stage biotech, a 'hold' recommendation is appropriate for investors to monitor progress closely.

Keywords

Cell therapy, Autoimmune diseases, CAR T, Stiff Person Syndrome, Myasthenia Gravis, Lupus Nephritis, Multiple Sclerosis, Rheumatoid Arthritis, Biopharmaceutical, Clinical trials, KYV-101, KYV-102, Neuroimmunology